Gene expression time-series analysis of Camptothecin effects in U87-MG and DBTRG-05 glioblastoma cell lines

详细信息    查看全文

• 作者：Elena Morandi (1)
  Cinzia Severini (1)
  Daniele Quercioli (1)
  Giovanni D'Ario (2)
  Stefania Perdichizzi (3)
  Miriam Capri (4)
  Giovanna Farruggia (5)
  Maria Grazia Mascolo (1)
  Wolfango Horn (1)
  Monica Vaccari (1)
  Roberto Serra (6)
  Annamaria Colacci (1)
  Paola Silingardi (1)
  
• 刊名：Molecular Cancer
• 出版年：2008
• 出版时间：December 2008
• 年：2008
• 卷：7
• 期：1
• 全文大小：1540KB
• 参考文献：1. Hsiang YH, Lihou MG, Liu LF: Arrest of replication forks by drug-stabilized topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. / Cancer Res 1989, 49:5077鈥?082.
  2. Liu LF, Desai SD, LI T, Mao Y, Sun M, Sim S: Mechanism of action of camptothecin. / Ann N Y Acad Sci 2000, 922:1鈥?6. CrossRef
  3. Carson JP, Zhang N, Frampton GM, Gerry NP, Lenburg ME, Christman MF: Pharmacogenomic identification of targets for adjuvant therapy with the topoisomerase poison camptothecin. / Cancer Res 2004, 64:2096鈥?104. CrossRef
  4. Han Z, Wei W, Dunaway S, Darnowski JW, Calabresi P, Sedivy J, Hendrickson EA, Balan KV, Pantazis P, Wyche JH: Role of p21 in Apoptosis and senescence of human colon cancer cells treated with camptothecin. / J Biol Chem 2002, 277:17154鈥?7160. CrossRef
  5. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS: p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. / Oncogene 2004, 23:1283鈥?290. CrossRef
  6. Eom YW, Kim MA, Park SS, Goo MJ, Kwon HJ, Sohn S, Kim WH, Yoon G, Choi KS: Two distinctive modes of cell death induced by doxorubicin: apoptosis and cell death through mitotic catastrophe accompanied by senescence-like phenotype. / Oncogene 2005, 24:4765鈥?777. CrossRef
  7. Zhou BB, Elledge SJ: The DNA damage response: putting checkpoints in perspective. / Nature 2000, 408:433鈥?39. CrossRef
  8. Ljungman M: Activation of DNA damage signaling. / Mutat Res 2005, 577:203鈥?16.
  9. Flatten K, Dai NT, Vroman BT, Loegering D, Erlichman C, Karnitz LM, Kaufmann SH: The role of Checkpoint kinase 1 in sensitivity to topoisomerase I poisons. / J Biol Chem 2005,280(14):14349鈥?4355. CrossRef
  10. Huang TT, Wuezberger-Davis SM, Seuzer BJ, Shumway SD, Kurama T, Boothman DA, Miyamoto S: NF-kB activation by camptothecin: a linkage between nuclear DNA damage and cytoplasmic signaling events. / J Biol Chem 2000, 275:9501鈥?509. CrossRef
  11. Janssens S, Tschopp J: Signals from within: the DNA-damage-induced NF-kappaB response. / Cell Death Differ 2006, 13:773鈥?84. CrossRef
  12. Amundson SA, Do KT, Vinikor L, Koch-Paiz CA, Bittner ML, Trent JM, Meltzer P, Fornace AJ Jr: Stress specific signatures: expression profiling of p53 wild-type and -null human cells. / Oncogene 2005, 24:4572鈥?579. CrossRef
  13. Zhou Y, Gwadry FG, Reinhold WC, Miller LD, Smith LH, Scherf U, Liu ET, Kohn KW, Pommier Y, Weinstein JN: Transcriptional regulation of mitotic genes by camptothecin-induced DNA damage: Microarray analysis of dose- and time-dependent effects. / Cancer Res 2002, 62:1688鈥?695.
  14. Ullmannova V, Haskovec C: Gene expression during camptothecin-induced apoptosis in human myeloid leukemia cell line ML-2. / Neoplasma 2004, 51:175鈥?80.
  15. Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR: In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. / Mol Cancer Ther 2005, 4:885鈥?00. CrossRef
  16. Reinhold WC, Kouros-Mehr H, Kohn KW, Maunakea AK, Lababidi S, Roschke A, Stover K, Alexander J, Pantazis P, Miller L, Liu E, Kirsch IR, Urasaki Y, Pommier Y, Weinstein JN: Apoptotic susceptibility of cancer cells selected for camptothecin resistance: gene expression profiling, functional analysis, and molecular interaction mapping. / Cancer Res 2003, 63:1000鈥?011.
  17. Friedman HS, Keir ST, Houghton PJ: The emerging role of Irinotecan (CPT11) in the treatment of malignant glioma in brain tumours. / Cancer 2003, 97:2359鈥?362. CrossRef
  18. Bent MJ, Hegi ME, Stupp R: Recent developments in the use of chemotherapy in brain tumours. / Eur J Cancer 2006, 42:582鈥?88. CrossRef
  19. Morandi E, Zingaretti C, Chiozzotto D, Severini C, Semeria A, Horn W, Vaccari M, Serra R, Silingardi P, Colacci A: A cDNA-microarray analysis of camptothecin resistance in glioblastoma cell lines. / Cancer Lett 2006, 231:74鈥?6. CrossRef
  20. Kahlem P, Dorken B, Schmitt CA: Cellular senescence in cancer treatment: friend or foe. / J Clin Invest 2004, 113:169鈥?74.
  21. Campisi J: Senescent cells, tumor suppression, and organism aging: good citizens, bad neighbors. / Cell 2005, 120:513鈥?22. CrossRef
  22. Roberson RS, Kussick SJ, Vallieres E, Chen SJ, Wu DY: Escape from therapy-induced accelerated cellular senescence in p53-null lung cancer cells and in human lung cancers. / Cancer Res 2005, 65:2795鈥?803. CrossRef
  23. Wu H, Kerr K, Cui X, Churchill GA: MAANOVA: a software package for the analysis of spotted cDNA microarray experiments. / The analysis of gene expression data: methods and software / (Edited by: Parmigiani G, Garett ES, Irizarry RA, et al). Heidelberg: Springer 2003, 313鈥?41. CrossRef
  24. Zeeberg BR, Qin H, Narasimhan S, Sunshine M, Cao H, Kane DW, Reimers M, Stephens RM, Bryant D, Burt SK, Elnekave E, Hari DM, Wynn TA, Cunningham-Rundles C, Stewart DM, Nelson D, Weinstein JN: High-Throughput GoMiner, an 'industrial-strength' integrative gene ontology tool for interpretation of multiple-microarray experiments, with application to studies of Common Variable Immune Deficiency (CVID). / BMC Bioinformatics 2005, 6:1鈥?8. CrossRef
  25. Hosack DA, Glynn D Jr, Sherman BT, Lane HC, Lempicki RA: Identifying Biological Themes within Lists of Genes with EASE. / Genome Biology 2003, 4:R70. CrossRef
  26. Li Y, Dowbenko D, Lasky LA: AKT/PKB phosphorylation of p21Cip/WAF1 enhances protein stability of p21Cip/WAF1 and promotes cell survival. / J Biol Chem 2002, 277:11352鈥?1361. CrossRef
  27. Kho PS, Wang Z, Zhuang L, Li Y, Chew JL, Ng HH, Liu ET, Yu Q: p53-regulated transcriptional program associated with genotoxic stress-induced apoptosis. / J Biol Chem 2004, 279:21183鈥?1192. CrossRef
  28. Fukuda S, Pelus LM: Survivin, a cancer target with an emerging role in normal adult tissues. / Mol Cancer Ther 2006, 5:1087鈥?098. CrossRef
  29. Xie D, Zeng YX, Wang HJ, Wen JM, Tao Y, Sham JS, Guan XY: Expression of cytoplasmic and nuclear Survivin in primary and secondary human glioblastoma. / Br J Cancer 2006, 94:108鈥?14. CrossRef
  30. Crawfords DF, Piwnica-Worms H: The G2 DNA damage checkpoint delays expression of genes encoding mitotic regulators. / J Biol Chem 2001,276(40):37166鈥?7177. CrossRef
  31. Gjoerup OV, Wu J, Chandler-Militello D, Williams GL, Zhao J, Schaffhausen B, Jat PS, Roberts TM: Surveillance mechanism linking Bub1 loss to the p53 pathway. / Proc Natl Acad Sci USA 2007, 104:8334鈥?339. CrossRef
  32. Vogel C, Kienitz A, Muller R, Bastians H: The mitotic spindle checkpoint is a critical determinant for topoisomerase-based chemotherapy. / J Biol Chem 2005, 280:4025鈥?028. CrossRef
  33. Du Y, Yin F, Hu S, Wang J, Xie H, Hong L, Fan D: Depression of Mad2 inhibits apoptosis of gastric cancer cells by upregulating Bcl-2 and interfering mitochondrion pathway. / Biochem Biophys Res Commun 2006, 345:1092鈥?098. CrossRef
  34. Dyson N: The regulation of E2F by pRB-family proteins. / Genes Dev 1998, 12:2245鈥?262. CrossRef
  35. Maehara K, Yamakoshi K, Ohtani N, Kubo Y, Takahashi A, Arase S, Jones N, Hara E: Reduction of total E2F/DP activity induces senescence-like cell cycle arrest in cancer cells lacking functional pRB and p53. / J Cell Biol 2005, 168:553鈥?60. CrossRef
  36. Ishida S, Huang E, Zuzan H, Spang R, Leone G, West M, Nevins JR: Role for E2F in control of both DNA replication and mitotic functions as revealed from DNA microarray analysis. / Mol Cell Biol 2001, 21:4684鈥?699. CrossRef
  37. Arango D, Mariadason JM, Wilson AJ, Yang W, Corner GA, Nicholas C, Aranes MJ, Augenlicht LH: c-Myc overexpression sensitises colon cancer cells to camptothecin-induced apoptosis. / Brit J Cancer 2003, 89:1757鈥?765. CrossRef
  38. Adachi S, Obaya AJ, Han Z, Ramos-Desimone N, Wyche JH, Sedivy J: c-myc is necessary for DNA damage-induced apoptosis in the G2 phase of the cell cycle. / Mol Cell Biol 2001, 21:4929鈥?937. CrossRef
  39. Guney I, Wu. S, Sedivy JM: Reduced c-Myc signaling triggers telomere-independent senescence by regulating Bmi-1 and p16INK4a. / Proc Natl Acad Sci USA 2006, 103:3645鈥?650. CrossRef
  40. Wu CH, van Riggelen J, Yetil A, Fan AC, Bachereddy P, Felsher DW: Cellular senescence is an important mechanism of tumor regression upon c-myc inactivation. / Proc Natl Acad Sci USA 2007, 104:13028鈥?3033. CrossRef
  41. Gee JR, Ding Q, Keller JN: Age-related alterations of Apolipoprotein E and Interleukin-1beta in the aging brain. / Biogerontology 2006, 7:69鈥?9. CrossRef
  42. Hardy K, Mansfield L, Mackay A, Benvenuti S, Ismail S, Arora P, O'Hare MJ, Jat PS: Transcriptional networks and cellular senescence in human mammary fibroblast. / Mol Biol Cell 2005, 16:943鈥?53. CrossRef
  43. Coussens LM, Werb Z: Inflammation and cancer. / Nature 2002, 420:860鈥?67. CrossRef
  44. Krelin Y, Voronov E, Dotan S, Elkabets M, Reich E, Fogel M, Huszar M, Iwakura Y, Segal S, Dinarello CA, Apte RN: Interleukin-1beta-driven inflammation promotes the development and invasiveness of chemical carcinogen-induced tumors. / Cancer Res 2007, 67:1062鈥?071. CrossRef
  45. Apte RN, Krelin Y, Song X, Dotan S, Recih E, Elkabets M, Carmi Y, Dvorkin T, White RM, Gayvoronsky L, Segal S, Voronov E: Effects of micro-environment- and malignant cell-deriverd inteleukin-1 in carcinogenesis, tumors invasiveness and tumors-host interactions. / Eur J Cancer 2006, 42:751鈥?59. CrossRef
  46. Cui X, Hwang JT, Qiu J, Blades NJ, Churchill GA: Improved statistical tests for differential gene expression by shrinking variance components estimates. / Biostatistics 2005, 6:59鈥?5. CrossRef
  47. Benjamini Y, Hochberg Y: Controlling the false discovery rate: a practical and powerful approach to multiple testing. / J R Statist Soc B 1995, 57:289鈥?00.
  48. Livak KJ, Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. / Methods 2001, 25:402鈥?08. CrossRef
  
• 作者单位：Elena Morandi (1)
  Cinzia Severini (1)
  Daniele Quercioli (1)
  Giovanni D'Ario (2)
  Stefania Perdichizzi (3)
  Miriam Capri (4)
  Giovanna Farruggia (5)
  Maria Grazia Mascolo (1)
  Wolfango Horn (1)
  Monica Vaccari (1)
  Roberto Serra (6)
  Annamaria Colacci (1)
  Paola Silingardi (1)
  
  1. Excellence Environmental Carcinogenesis, Lab. Mater, Environmental Protection and Health Prevention Agency 鈥?Emilia-Romagna Region (ER-EPA), Viale Filopanti 22, 40126, Bologna County, Italy
  2. The FIRC Institute of Molecular Oncology Foundation, Via Adamello 16, 20139, Milan, Italy
  3. Department of Experimental Pathology-Cancer Research Section, University of Bologna, Viale Filopanti 22, 40126, Bologna, Italy
  4. CIG, Interdepartmental Research Centre "L. Galvani", University of Bologna, Via S. Giacomo 12, 40126, Bologna, Italy
  5. Department of Biochemistry, University of Bologna, Via Irnerio 48, 40126, Bologna, Italy
  6. Department of Social, Cognitive and Quantitative Sciences, University of Modena and Reggio Emilia, Via Allegri 9, Reggio Emilia, Italy
  
• ISSN：1476-4598

文摘

Background The clinical efficacy of camptothecin (CPT), a drug specifically targeting topoisomerase I (TopoI), is under evaluation for the treatment of malignant gliomas. Due to the high unresponsiveness of these tumours to chemotherapy, it would be very important to study the signalling network that drives camptothecin outcome in this type of cancer cells. To address this issue, we had previously compared the expression profile of human U87-MG glioblastoma cells with that of a CPT-resistant counterpart, giving evidence that the development of a robust inflammatory response was the main transcriptional effect associated with CPT resistance. Here we report time-related changes and cell line specific patterns of gene expression after CPT treatment by using two p53 wild-type glioblastoma cell lines, U87-MG and DBTRG-05, with different sensitivities to TopoI inhibition. Results First, we demonstrated that CPT treatment brings the two cell lines to completely different outcomes: accelerated senescence in U87-MG and apoptosis in DBTRG-05 cells. Then, to understand the different susceptibility to CPT, we used oligo-microarray to identify the genes whose expression was regulated during a time-course treatment, ranging from 2 h to 72 h. The statistical analysis of microarray data by MAANOVA (MicroArray ANalysis Of VAriance) showed much less modulated genes in apoptotic DBTRG-05 cells (155) with respect to the senescent U87-MG cells (3168), where the number of down-regulated genes largely exceeded that of the up-regulated ones (80% vs. 20%). Despite this great difference, the two data-sets showed a large overlapping (60% circa) mainly due to the expression of early stress responsive genes. The use of High-Throughput GoMINER and EASE tools, for functional analysis of significantly enriched GO terms, highlighted common cellular processes and showed that U87-MG and DBTRG-05 cells shared many GO terms, which are related to the down-regulation of cell cycle and mitosis and to the up-regulation of cell growth inhibition and DNA damage. Furthermore, the down-regulation of MYC and DP1 genes, which act as key transcription factors in cell growth control, together with the inhibition of BUB1, BUB3 and MAD2 mRNAs, which are known to be involved in the spindle checkpoint pathway, were specifically associated with the execution of senescence in U87-MG cells and addressed as critical factors that could drive the choice between different CPT-inducible effectors programs. In U87-MG cells we also found inflammation response and IL1-beta induction, as late transcriptional effects of Topo I treatment but these changes were only partially involved in the senescence development, as shown by IL1-beta gene silencing. Conclusion By comparing the transcription profile of two glioblastoma cell lines treated with camptothecin, we were able to identify the common cellular pathways activated upon Topo I inhibition. Moreover, our results helped in identifying some key genes whose expression seemed to be associated with the execution of senescence or apoptosis in U87-MG and DBTRG-05 cells, respectively.